Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.

Autor: Lehmann BD; Department of Medicine, Vanderbilt University, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee., Abramson VG; Department of Medicine, Vanderbilt University, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee., Dees EC; Department of Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill., Shah PD; Department of Medicine, University of Pennsylvania, Philadelphia., Ballinger TJ; Department of Medicine, Indiana University, Indianapolis., Isaacs C; Department of Medical Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC., Santa-Maria CA; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland., An H; Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee., Gonzalez-Ericsson PI; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Sanders ME; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee., Newsom KC; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee., Abramson RG; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee., Sheng Q; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Hsu CY; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Shyr Y; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Wolff AC; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland., Pietenpol JA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Department of Biochemistry, Vanderbilt University, Nashville, Tennessee.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Feb 01; Vol. 10 (2), pp. 193-201.